Tachyon Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)Jeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso VenturesLumira VenturesPathway Bioventures+6 more
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inJason Camm(Director)Kasper Roet(Director)Tony DePasqua(President & CEO)Kevin Kalish(COO)Marcie Glicksman(VP Biology)
Co-investors20/20 HealthCare Partners LLCFlucas VenturesVU Venture PartnersDolby Family Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.